Laisse-moi chercher les données sur ce composé avant d’analyser.

Toutes les données sont là. Voici l’analyse puis la fiche complète :

---

Analyse mots-clés 5-Amino-1MQ

Mot-clé principal : 5-amino-1mq buy — KD = 0, transactionnel pur, quasi zéro concurrence.

Mot-clé	Volume	KD	Choix
buy 5 amino 1mq	110	15	Secondaire — H2
5-amino-1mq buy	70	0	Principal — KD = 0
buy 5-amino-1mq	50	5	Variante — corps du texte
5-amino-1mq where to buy	30	7	Secondaire — H2

---

TECHNICAL SEO SETTINGS

Focus Keyword : 5-amino-1mq buy
Secondary Keywords : buy 5 amino 1mq / buy 5-amino-1mq / 5-amino-1mq where to buy
SEO Title : 5-Amino-1MQ Buy — NNMT Inhibitor For Sale | Ships in 48h
Slug : /5-amino-1mq-buy
Meta Description : Ready to buy 5-amino-1MQ? Shop the NNMT inhibitor for fat metabolism and NAD+ support online — COA verified, ships in 1 to 2 business days across the US. No clinic required.
Schema : Product + FAQPage
Canonical : https://peptidenearme.com/5-amino-1mq-buy

---

 

What Is 5-Amino-1MQ and Why Are Researchers Buying It?

5-Amino-1MQ sits in a different research category from the tissue repair and hormone optimization compounds on the rest of this site. Rather than targeting receptors in the brain or stimulating growth hormone release, it works at the level of an enzyme inside fat cells themselves.

5-Amino-1MQ, also known as 5-amino-1-methylquinolinium, is a small-molecule selective inhibitor of nicotinamide N-methyltransferase — an enzyme that is overexpressed in the adipose tissue of obese individuals and plays a central role in metabolic regulation. University of Texas Health Science Center researchers developed and characterized it starting around 2017, and it has since generated a growing body of preclinical literature focused on fat metabolism, NAD+ preservation, and body composition.

One important clarification upfront: 5-Amino-1MQ is technically a small molecule, not a peptide. Nevertheless, it is widely supplied alongside peptide reference materials in weight and metabolism research programs, which is why it appears in our catalog alongside compounds like Retatrutide and AOD-9604.

The NNMT Enzyme — Why Inhibiting It Matters

NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine, commonly known as SAM, onto nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. The problem: this process depletes both SAM and nicotinamide — the body’s methyl donor pool and a key NAD+ precursor.

When NNMT is overactive, as it tends to be in obese adipose tissue, fat cells become metabolically sluggish. They deplete the cellular substrate needed for energy regulation and appear to actively suppress their own metabolic activity. 5-Amino-1MQ is designed to inhibit that enzyme, thereby preserving SAM and nicotinamide, elevating cellular energy metabolism substrates, and shifting adipose tissue toward fat oxidation.

How This Differs From GLP-1 Medications

5-Amino-1MQ targets fat cells directly by inhibiting NNMT, while GLP-1 agonists work through appetite suppression and insulin signaling. They use completely different mechanisms, which is why researchers have begun exploring them as complementary tools rather than competing alternatives. Notably, it reduces fat mass without affecting muscle and without suppressing appetite — which distinguishes it from virtually every other fat metabolism compound in active research.

For researchers already exploring GLP-1 compounds, our metabolic peptide catalog covers both approaches.

5-Amino-1MQ Buy — Our Products

IMAGE: buy-5-amino-1mq-10mg-50mg-options-coa.jpg
Alt text: buy 5 amino 1mq 10mg and 50mg options with COA third party tested

5-Amino-1MQ 10mg — Entry Research Format

Designed for conservative dosing protocols or shorter research cycles. Every vial ships with a lot matched COA, a reconstitution guide, and a dosage reference card.

Concentration : 10mg per vial
Purity : 98% minimum, HPLC verified, third party tested
Includes : reconstitution guide, dosage reference, COA
Delivery : 1 to 2 business days, discreet and tracked

5-Amino-1MQ 50mg — Standard Research Supply

The format most commonly referenced in preclinical protocols. Better milligram per dollar value, same purity standards. Suitable for full cycle research at documented dosing ranges.

Concentration : 50mg per vial
Purity : 99% minimum, HPLC verified, third party tested
Includes : reconstitution guide, full protocol reference, COA
Delivery : 1 to 2 business days, discreet and tracked

Buy 5 Amino 1MQ — What the Preclinical Research Shows

Fat Mass Reduction Without Muscle Loss

The most cited preclinical finding from NNMT inhibition studies is fat mass reduction without lean tissue loss. Neelakantan H et al., published in Biochemical Pharmacology in 2020, characterized 5-amino-1MQ as a selective small-molecule NNMT inhibitor and demonstrated fat loss effects in mouse models of diet-induced obesity without affecting food intake or lean muscle mass.

Separately, before and after comparisons from animal research revealed that the treated group experienced a 30% decrease in the size of individual adipocytes compared to the untreated control group. Furthermore, blood cholesterol levels remained stable during the observation period, suggesting that the weight reduction was primarily driven by fat oxidation rather than general caloric restriction.

NAD+ Preservation and Cellular Energy

By inhibiting NNMT, 5-Amino-1MQ preserves nicotinamide — a direct NAD+ precursor — in adipose tissue. This makes it complementary to direct NAD+ precursors like NMN and NR, since they support NAD+ synthesis from different metabolic angles. Additionally, SAM preservation supports methylation balance and the activation of SIRT1, frequently referenced as the longevity gene, which enhances mitochondrial function and fat oxidation through a separate pathway.

Muscle Preservation

In preclinical models, NNMT inhibition produced fat loss effects without reducing lean muscle mass. This profile places 5-Amino-1MQ in a distinct category from most caloric restriction or appetite based weight management approaches, where muscle preservation is typically a secondary concern rather than a primary outcome.

Metabolic Efficiency — What Users Report

Community reports consistently reference increased cellular energy and a sense of improved vigor without appetite suppression. Unlike typical GLP-1 medications which act on a single receptor, 5-Amino-1MQ operates through the NNMT enzyme in peripheral adipose tissue, leaving appetite regulation pathways unaffected.

5-Amino-1MQ Where to Buy — Price and Source Comparison

Searching for 5-amino-1MQ where to buy returns a mixed landscape — some legitimate research suppliers, some storefronts with no documentation, and clinic pricing that includes prescription and consultation fees layered on top of the compound cost. Here is the honest 2026 market picture:

Source	Price	COA Available	Delivery
Peptide Near Me	$XX per vial	Lot matched, every batch	48 hours
Compounding pharmacy 503A	Varies with prescription	Yes, under physician	Requires prescription
Generic research sites	$20 to $60	Rarely	5 to 10 days
Wellness clinics	$150 to $400 per month	Sometimes	Appointment required

Compounded 5-amino-1MQ from licensed 503A pharmacies is the typical US dispensing pathway when a physician supervises the protocol. When you buy 5-amino-1MQ directly from our store as a research compound, you pay for the compound itself with no prescription requirement and no consultation markup added.

Check Current Pricing

5-Amino-1MQ Dosage — Protocol Reference From Published Research

No FDA approved dosing protocol exists for 5-Amino-1MQ. The following reference draws from published preclinical data and documented research protocols.

Dosage Reference Table

Protocol	Daily Dose	Administration	Cycle Length
Conservative entry	50 to 100mcg per day	Subcutaneous or oral	6 to 8 weeks
Standard research	150 to 300mcg per day	Subcutaneous	6 to 8 weeks
Research study reference	150 to 300mcg per kg body weight	Subcutaneous	Protocol dependent

Cycling Recommendations

A common cycling approach involves using the compound for 6 to 8 weeks followed by a 4 week break. This approach reflects general preclinical protocol design rather than established human trial data, since no published human clinical trials for 5-Amino-1MQ exist as of 2026. Conservative protocols begin at 0.2 to 0.25mg daily, allowing assessment of individual response before increasing dose.

Administration Format

5-Amino-1MQ is available in both injectable and oral capsule formats. Injectable subcutaneous administration follows the same approach as other research peptides. Oral capsule formats, typically supplied at 50mg per capsule, represent an alternative delivery method that some researchers prefer for daily dosing convenience.

5-Amino-1MQ Side Effects and Safety Profile

5-Amino-1MQ is generally considered well tolerated in the preclinical literature. However, given the complete absence of published human clinical trial data, the full human safety profile remains unknown.

What Preclinical Research Reported

Animal studies did not flag significant adverse effects at the doses studied. The mechanism remains localized to peripheral tissues where the NNMT enzyme is most active, which limits the potential for CNS related side effects that accompany centrally acting compounds.

Unknown Risks

Because no published human trials exist, unknown effects on organs such as the liver and kidneys remain a genuine concern. Anyone with pre existing liver or kidney conditions should approach this compound with additional caution and discuss it with a physician before use.

Who Should Exercise Particular Caution

Pregnant or breastfeeding individuals should not use this compound. People with pre existing metabolic conditions being managed by medication should consult a physician before adding an NNMT inhibitor to their protocol. Additionally, individuals with a history of methylation related conditions should discuss SAM pathway modulation with a healthcare provider first, given that NNMT inhibition directly affects the methyl donor pool.

5-Amino-1MQ vs Other Metabolic Research Compounds — Key Differences

	5-Amino-1MQ	Retatrutide	AOD-9604	Semaglutide
Mechanism	NNMT inhibition in adipose tissue	Multi-receptor GLP-1 agonist	GH fragment, fat oxidation	GLP-1 receptor agonist
Primary effect	Fat cell metabolism, NAD+ preservation	Metabolic weight reduction	Fat oxidation	Appetite suppression, insulin signaling
Muscle preservation	Documented in preclinical models	Limited data	Limited data	Concern in some studies
Appetite suppression	No	Yes	Minimal	Yes
Human trial data	None published as of 2026	Phase 3 active	Limited	Extensive, FDA approved
Complementary to GLP-1	Yes, different mechanism	N/A	Partial	N/A

The table above highlights the most important distinction for research purposes: 5-Amino-1MQ does not suppress appetite, does not work through GLP-1 pathways, and does not affect lean muscle mass in preclinical models. As a result, researchers studying it most frequently explore it either as a standalone metabolic intervention or as a complement to GLP-1 therapy rather than a replacement for it.

For researchers exploring the GLP-1 adjacent space alongside this compound, our full metabolic category including Retatrutide and Semaglutide is available here.

5-Amino-1MQ Regulatory Status in 2026

5-Amino-1MQ is not FDA approved for any indication. It is a preclinical research compound with no published human clinical trials as of April 2026. Compounded 5-amino-1MQ is available through licensed 503A pharmacies under physician prescription for off label use. As a research compound, it is legal to purchase without a prescription through registered research compound retailers.

For FDA information on compounding regulations and the 503A pathway, refer to FDA.gov compounding guidance.

Current status at a glance: not FDA approved for any human indication. No completed or registered Phase 1, 2, or 3 human trials published as of April 2026. Available as a research compound without prescription. Available through 503A compounding pharmacies with physician prescription. Developed from University of Texas Health Science Center research beginning in 2017.

Ready to Complete Your 5-Amino-1MQ Buy?

You have reviewed the mechanism. You understand how NNMT inhibition differs from appetite based and GLP-1 approaches. You know the preclinical data and the honest limits of what has been studied in humans. The final variable in your 5-amino-1MQ buy decision is sourcing — and that is the step that determines what actually arrives at your door.

Every vial in our buy 5-amino-1MQ catalog ships with a lot matched COA. We run HPLC testing on every batch before it enters inventory. Orders placed before 2pm go out the same day, and a real team member handles any post purchase issue rather than an automated response system.

Buy 5-Amino-1MQ 10mg
Buy 5-Amino-1MQ 50mg
Questions Before You Order? Contact Us Here

Free shipping on orders above $200. Discreet outer packaging. Fully tracked from dispatch.

Frequently Asked Questions — 5-Amino-1MQ Buy

What is 5-Amino-1MQ?

5-Amino-1MQ is a selective small-molecule inhibitor of nicotinamide N-methyltransferase, or NNMT, an enzyme overexpressed in the adipose tissue of obese individuals. By inhibiting NNMT, it preserves SAM and nicotinamide in fat cells, elevating NAD+ precursor availability and shifting cellular metabolism toward fat oxidation. University of Texas Health Science Center researchers developed it starting around 2017.

Is 5-Amino-1MQ a peptide?

Technically, no. 5-Amino-1MQ is a small molecule rather than a peptide chain. However, it is frequently supplied alongside peptide reference materials in metabolism and weight research programs, and it is categorized within the metabolic research compound space for that reason.

Where can I buy 5-amino-1MQ?

You can purchase 5-amino-1MQ through our store as a research compound without a prescription, through licensed 503A compounding pharmacies under physician prescription, or through other research compound retailers. When evaluating sources, verify that every vial carries a lot matched COA with HPLC verified purity  that confirmation is the minimum standard for a compound at this research stage.

Does 5-Amino-1MQ suppress appetite?

No. Unlike GLP-1 medications, 5-Amino-1MQ does not suppress appetite. Its mechanism operates in peripheral adipose tissue through NNMT inhibition, leaving appetite regulation pathways unaffected. This distinction makes it a candidate for combination research with GLP-1 compounds rather than a direct substitute.

What are the side effects of 5-Amino-1MQ?

Preclinical animal studies did not flag significant adverse effects at the doses studied. Because no published human clinical trials exist as of 2026, the full human side effect profile is unknown. Users with pre existing liver, kidney, or methylation related conditions should consult a physician before use.

How does 5-Amino-1MQ relate to NAD+ therapy?

By inhibiting NNMT, 5-Amino-1MQ preserves nicotinamide in adipose tissue, which is a direct NAD+ precursor. This makes it complementary to direct NAD+ precursors like NMN and NR, since they address NAD+ availability through different metabolic pathways. Together, they represent a multi angle approach to cellular energy metabolism.

What is the typical 5-Amino-1MQ dosage?

Conservative protocols begin at 50 to 100mcg daily. Standard research protocols referenced in the preclinical literature use 150 to 300mcg daily, administered subcutaneously. Cycling of 6 to 8 weeks on followed by a 4 week break is the most commonly documented approach. No standardized human dosing protocol exists.

Is 5-Amino-1MQ legal to buy in 2026?

Yes, as a research compound. 5-Amino-1MQ is not FDA approved and has no completed human trials, but it is legal to purchase as a research compound through registered research compound retailers in the US. Compounded versions are also available through licensed 503A pharmacies under physician prescription.

How does 5-Amino-1MQ compare to Retatrutide or Semaglutide?

These compounds operate through completely different mechanisms. Retatrutide and Semaglutide work through GLP-1 and related receptor pathways to suppress appetite and influence insulin signaling. 5-Amino-1MQ targets the NNMT enzyme directly in adipose tissue, without affecting appetite or lean muscle mass in preclinical models. Researchers explore them as complementary tools rather than direct alternatives.

Can 5-Amino-1MQ be combined with GLP-1 medications?

Preclinical research and clinical observations suggest that 5-Amino-1MQ and GLP-1 agonists use completely different mechanisms and can be complementary. One clinical perspective describes using it alongside GLP-1 therapy for patients who want to maximize fat loss while preserving lean tissue. Given the absence of human trial data on combinations, medical supervision is strongly advisable before attempting any combined protocol.